06 Nov Key appointment to BTS Board of Dr John Chiplin PhD
Biotherapy Services appoints John Chiplin as Chairman
We are pleased to announce the key appointment to the BTS Board of Dr John Chiplin PhD as Chairman. John is Managing Director of Newstar Ventures Ltd. and also Chairman of Scancell Holdings plc (LSE:SCLP) and has extensive UK and International experience and expertise in the life sciences and technology arenas from both an operational and investment perspective. As the head of the ITI Life sciences investment fund in the UK, Dr Chiplin negotiated significant funding with the UK Government and has managed the mergers, acquisitions and listing of a number of blue chip companies. BTS will benefit hugely from John’s expertise and corporate governance. Further details of John’s numerous accomplishments can be found on our website.
Recent significant transactions in the Life Sciences and Techgnology space that Dr Chiplin has been involved in include the following:
2016 to current Executive Chairman Scancell Holdings Plc (SCL.L)
2014- 2016 CEO of Polynoma LLC
Other Key Transactions: Acacia Biopharma [Euronext IPO], FV Systems [acquired by Go Daddy] Aldata Pty [Australian IPO], Benitec Biopharm [USA IPO], Medistem Inc [acquired by Intrexon], Arana Therapeutics [acquired by Cephalon], Ignite Group [MBO] and Domantis [acquired by GSK].